Opinion: miRNAs - The new wave of molecular cancer therapeutics

Hernando Lopez-Bertoni; John Laterra

doi:10.1016/j.tranon.2021.101064

Opinion: miRNAs - The new wave of molecular cancer therapeutics

Transl Oncol. 2021 Jun;14(6):101064. doi: 10.1016/j.tranon.2021.101064. Epub 2021 Mar 12.

Authors

Hernando Lopez-Bertoni¹, John Laterra²

Affiliations

¹ Hugo W. Moser Research Institute at Kennedy Krieger, 707N. Broadway, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA. Electronic address: lopezbertoni@kennedykrieger.org.
² Hugo W. Moser Research Institute at Kennedy Krieger, 707N. Broadway, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA; Department of Oncology, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA. Electronic address: laterra@kennedykrieger.org.

Abstract

Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how miRNAs are becoming the next-generation RNAi therapeutic, the advances in delivery vehicles for in vivo miRNA delivery, and where miRNA technology stands in terms of clinical translation.

Abstract

Grants and funding